Clinical Research Directory
Browse clinical research sites, groups, and studies.
Impact of Short-term Intensive De-escalation Therapy on Long-term Regimen Simplification
Sponsor: Yanbing Li
Summary
Despite advances in diabetes management, many patients with type 2 diabetes in China fail to achieve optimal glycemic control. One of the possible reasons is associated with the delay in therapeutic decision making that lags behind glycemic rise. The investigators design this study and presume that using vildagliptin and metformin in combination with basal insulin as sequential treatment after intensive insulin therapy, might better modulate the dual islet hormone dysfunction than traditionally stepwise upgrading therapy pattern in patients with poorly controlled T2DM, and thus lead to a glucose normalization, β-cell function improvement and therapy simplification.
Official title: Impact of Short-term Intensive De-escalation Therapeutic Strategy on Long-term Regimen Simplification in Poorly Controlled Type 2 Diabetes: a National Multicenter, Prospective, Randomized Trial
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
276
Start Date
2019-05-01
Completion Date
2026-03-31
Last Updated
2026-09-08
Healthy Volunteers
No
Conditions
Interventions
CSII and thereafter combination therapy, followed up with wearable devices
Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin; Wearable devices will be used to manage and follow-up the participants.
CSII and thereafter combination therapy
Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin.
Basal insulin treatment without wearables
The participants will be applied the combination therapy of basal insulin, metformin and vildagliptin for the entire 12 weeks.
Locations (1)
Department of endocrinology, FAH-SYSU
Guangzhou, Guangdong, China